Breaking News

WuXi PharmaTech, PBI In Biomarker Alliance

Gains access to PBI’s biomarker assays to support clinical testing services

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi PharmaTech and Pacific Biomarkers (PBI) have entered a collaboration under which PBI will provide access to its portfolio of validated biomarker assays to support WuXi’s clinical trial testing services, including bioanalysis and central lab services for pharma and biopharma companies performing clinical trials in China. PBI’s biomarkers include therapeutics areas of cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters